Diagnostic performance of 14-3-3η and anti-carbamylated protein antibodies in Rheumatoid Arthritis in Han population of Northern China

•Single and multiple indicators can be combined together for identification of RA.•Positive of any two markers or only anti-CCP tend to be diagnosed as RA.•Four indicators were significantly positively correlated with each other. As we already know, Rheumatoid arthritis (RA) cannot be excluded when...

Full description

Saved in:
Bibliographic Details
Published inClinica chimica acta Vol. 502; pp. 102 - 110
Main Authors Zhang, Yuan, Liang, Yongming, Feng, Limei, Cui, Liyan
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.03.2020
Subjects
Online AccessGet full text

Cover

Loading…
Abstract •Single and multiple indicators can be combined together for identification of RA.•Positive of any two markers or only anti-CCP tend to be diagnosed as RA.•Four indicators were significantly positively correlated with each other. As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP. Serum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value. The levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36–15.7], 30.7;[25.7–35.6], 1.90;[1.70–2.01], 15.8;[10.8–20.8], respectively) compared with either interference-control group (1.24;[1.07–1.41], 0.64;[0.42–0.86], 0.51;[0.46–0.57], 0.33;[0.23–0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99–1.08], 0.49;[0.38–0.59], 0.28;[0.21–0.35], 0.55;[0.27–0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value. The results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized.
AbstractList •Single and multiple indicators can be combined together for identification of RA.•Positive of any two markers or only anti-CCP tend to be diagnosed as RA.•Four indicators were significantly positively correlated with each other. As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP. Serum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value. The levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36–15.7], 30.7;[25.7–35.6], 1.90;[1.70–2.01], 15.8;[10.8–20.8], respectively) compared with either interference-control group (1.24;[1.07–1.41], 0.64;[0.42–0.86], 0.51;[0.46–0.57], 0.33;[0.23–0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99–1.08], 0.49;[0.38–0.59], 0.28;[0.21–0.35], 0.55;[0.27–0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value. The results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized.
As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP. Serum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value. The levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36-15.7], 30.7;[25.7-35.6], 1.90;[1.70-2.01], 15.8;[10.8-20.8], respectively) compared with either interference-control group (1.24;[1.07-1.41], 0.64;[0.42-0.86], 0.51;[0.46-0.57], 0.33;[0.23-0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99-1.08], 0.49;[0.38-0.59], 0.28;[0.21-0.35], 0.55;[0.27-0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value. The results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized.
As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP.OBJECTIVESAs we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP.Serum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value.METHODSerum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value.The levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36-15.7], 30.7;[25.7-35.6], 1.90;[1.70-2.01], 15.8;[10.8-20.8], respectively) compared with either interference-control group (1.24;[1.07-1.41], 0.64;[0.42-0.86], 0.51;[0.46-0.57], 0.33;[0.23-0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99-1.08], 0.49;[0.38-0.59], 0.28;[0.21-0.35], 0.55;[0.27-0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value.RESULTThe levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36-15.7], 30.7;[25.7-35.6], 1.90;[1.70-2.01], 15.8;[10.8-20.8], respectively) compared with either interference-control group (1.24;[1.07-1.41], 0.64;[0.42-0.86], 0.51;[0.46-0.57], 0.33;[0.23-0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99-1.08], 0.49;[0.38-0.59], 0.28;[0.21-0.35], 0.55;[0.27-0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value.The results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized.CONCLUSIONThe results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized.
Author Feng, Limei
Zhang, Yuan
Liang, Yongming
Cui, Liyan
Author_xml – sequence: 1
  givenname: Yuan
  surname: Zhang
  fullname: Zhang, Yuan
– sequence: 2
  givenname: Yongming
  surname: Liang
  fullname: Liang, Yongming
– sequence: 3
  givenname: Limei
  surname: Feng
  fullname: Feng, Limei
– sequence: 4
  givenname: Liyan
  surname: Cui
  fullname: Cui, Liyan
  email: cliyan@163.com, cuiliyan2006@hotmail.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31862264$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUhS1URKeFB2CDsmST4L9kYrGqhpYiVSBVZW059jXjUWIH20HqE_SReAueqZ6ZwoJFF5Z1fc93ZJ1zhk588IDQW4Ibgkn3YddorRqKiWgIbTAhL9CK9GtWMy7oCVphjEXdi56corOUdmXkuCOv0CkjfUdpx1fo4ZNTP3xI2elqhmhDnJTXUAVbEV4Xpz-_K-VNOdnVWsVBTfejymCqOYYMzh82QzAOUlWm2y0sk8rBmeoi5m102R3er5Wv5jAvhXXB7-2_hrKH6KvN1nn1Gr20akzw5uk-R9-vLu821_XNt89fNhc3tWYtyzWxrOV80AqEaBWjnTbUcmKNbvuW9LgVVpuBDpbyAQ-95ZhxGGyLewEc94ado_dH3_L9nwukLCeXNIyj8hCWJCmjYs2YYLRI3z1Jl2ECI-foJhXv5d_wioAcBTqGlCLYfxKC5b4guZOlILkvSBIqS0GFWf_HaJcPmeSo3Pgs-fFIQonnl4Mok3ZQujIugs7SBPcM_QgsO6vf
CitedBy_id crossref_primary_10_1515_cclm_2021_1136
crossref_primary_10_1038_s41598_022_13750_9
crossref_primary_10_1111_1756_185X_14012
crossref_primary_10_3892_etm_2023_12364
crossref_primary_10_1111_1756_185X_14007
crossref_primary_10_1007_s10067_020_05524_3
crossref_primary_10_1002_jcla_24266
crossref_primary_10_1016_j_ejr_2024_11_002
crossref_primary_10_1080_08820139_2020_1817069
crossref_primary_10_1093_rheumatology_keae297
crossref_primary_10_1016_j_clinbiochem_2021_11_018
crossref_primary_10_3390_diagnostics12071661
Cites_doi 10.1186/s13075-016-1173-0
10.1136/annrheumdis-2013-204154
10.1093/rheumatology/kev250
10.1016/j.phrs.2018.11.009
10.3899/jrheum.140767
10.1186/s13075-015-0536-2
10.1002/art.39664
10.1002/art.40237
10.1002/art.40738
10.1258/000456303321016204
10.1371/journal.pone.0161141
10.1136/annrheumdis-2016-209248
10.5858/2004-128-1078a-EOLITC
10.1038/nrrheum.2011.76
10.1177/0961203317713141
10.1186/s13075-016-0975-4
10.1155/2015/915276
10.1136/annrheumdis-2015-207751
10.1002/art.40562
10.1136/annrheumdis-2015-208870
10.1186/s13075-018-1622-z
10.1007/s10067-017-3807-2
10.1186/s13075-016-1001-6
10.1186/ar4547
10.1002/art.1780310302
10.1073/pnas.1114465108
10.1002/art.37830
10.3899/jrheum.141385
10.3899/jrheum.131446
10.1186/s13075-016-0935-z
10.1136/ard.2010.138461
10.1186/s13075-015-0860-6
10.1002/art.40678
ContentType Journal Article
Copyright 2019 Elsevier B.V.
Copyright © 2019 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2019 Elsevier B.V.
– notice: Copyright © 2019 Elsevier B.V. All rights reserved.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1016/j.cca.2019.12.011
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1873-3492
EndPage 110
ExternalDocumentID 31862264
10_1016_j_cca_2019_12_011
S0009898119321801
Genre Journal Article
GroupedDBID ---
--K
--M
.55
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29B
4.4
457
4G.
53G
5GY
5VS
6J9
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAXUO
ABBQC
ABFNM
ABFRF
ABGSF
ABJNI
ABLVK
ABMAC
ABMZM
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DOVZS
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
G8K
GBLVA
HLW
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
LCYCR
LX3
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
RNS
ROL
RPZ
SBG
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSU
SSZ
T5K
WH7
WUQ
X7M
XPP
ZA5
ZGI
~02
~G-
AATTM
AAXKI
AAYWO
AAYXX
ABDPE
ABWVN
ACIEU
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
CITATION
NPM
PKN
7X8
ID FETCH-LOGICAL-c353t-1f3544bcae995a326cd2f41fdc58518059fcdb2bf24b0b8f4034ebf5089e408d3
IEDL.DBID .~1
ISSN 0009-8981
1873-3492
IngestDate Fri Jul 11 07:19:21 EDT 2025
Wed Feb 19 02:31:27 EST 2025
Tue Jul 01 03:32:03 EDT 2025
Thu Apr 24 22:56:59 EDT 2025
Fri Feb 23 02:48:58 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords Anti-carbamylated proteins antibodies (anti-CarP)
Rheumatoid arthritis (RA)
Rheumatoid factor (RF)
Anti-cyclic citrullinated peptide antibody (anti-CCP)
14-3-3η
Language English
License Copyright © 2019 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c353t-1f3544bcae995a326cd2f41fdc58518059fcdb2bf24b0b8f4034ebf5089e408d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 31862264
PQID 2329733932
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2329733932
pubmed_primary_31862264
crossref_primary_10_1016_j_cca_2019_12_011
crossref_citationtrail_10_1016_j_cca_2019_12_011
elsevier_sciencedirect_doi_10_1016_j_cca_2019_12_011
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2020
2020-03-00
2020-Mar
20200301
PublicationDateYYYYMMDD 2020-03-01
PublicationDate_xml – month: 03
  year: 2020
  text: March 2020
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Clinica chimica acta
PublicationTitleAlternate Clin Chim Acta
PublicationYear 2020
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Gong, Xu, Wu (b0110) 2017; 36
Koppejan, Trouw, Sokolove (b0055) 2016; 68
Shovman, Gilburd, Watad (b0105) 2019; 141
Tholen (b0140) 2004; 128
Bergum, Koro, Delaleu (b0040) 2016; 75
Brink, Verheul, Ronnelid (b0030) 2015; 17
Ross, Sweep (b0135) 2003; 40
Reed, Jiang, Kharlamova (b0160) 2016; 18
Shi, van de Stadt, Levarht (b0025) 2014; 73
van Beers-Tas, Marotta, Boers, Maksymowych, van Schaardenburg (b0100) 2016; 18
Shi, van Steenbergen, van Nies (b0035) 2015; 17
Montes, Regueiro, Perez-Pampin, Boveda, Gomez-Reino, Gonzalez (b0045) 2016; 11
Derksen, Trouw, Huizinga (b0080) 2018; 70
Carrier, Marotta, de Brum-Fernandes (b0115) 2016; 18
Truchetet, Dublanc, Barnetche (b0075) 2017; 69
Verheul, van Erp, van der Woude (b0050) 2016; 75
Ajeganova, van Steenbergen, Verheul (b0070) 2017; 76
Shi, Knevel, Suwannalai (b0015) 2011; 108
Shi, van de Stadt, Levarht (b0020) 2013; 65
van Venrooij, van Beers, Pruijn (b0005) 2011; 7
Wang, Pei, Wang, Sun, Hu, Dou (b0010) 2015; 2015
Verheul, Bohringer, van Delft (b0145) 2018; 70
Aletaha, Neogi, Silman (b0125) 2010; 69
Verheul, Shiozawa, Levarht (b0060) 2015; 54
Regueiro, Rodriguez-Rodriguez, Triguero-Martinez (b0155) 2019; 71
Gan, Trouw, Shi (b0065) 2015; 42
Kilani, Maksymowych, Aitken (b0090) 2007; 34
Massaro, Ceccarelli, Colasanti (b0175) 2018; 27
Maksymowych, Naides, Bykerk (b0150) 2014; 41
Arnett, Edworthy, Bloch (b0130) 1988; 31
Guan, Yang, Bai (b0095) 2019; 49
Pecani, Alessandri, Spinelli (b0165) 2016; 18
Ceccarelli, Perricone, Colasanti (b0170) 2018; 20
Maksymowych, van der Heijde, Allaart (b0085) 2014; 16
Maksymowych, Boire, van Schaardenburg (b0120) 2015; 42
Derksen (10.1016/j.cca.2019.12.011_b0080) 2018; 70
Shi (10.1016/j.cca.2019.12.011_b0015) 2011; 108
Verheul (10.1016/j.cca.2019.12.011_b0050) 2016; 75
Maksymowych (10.1016/j.cca.2019.12.011_b0150) 2014; 41
Maksymowych (10.1016/j.cca.2019.12.011_b0085) 2014; 16
Koppejan (10.1016/j.cca.2019.12.011_b0055) 2016; 68
Kilani (10.1016/j.cca.2019.12.011_b0090) 2007; 34
Shi (10.1016/j.cca.2019.12.011_b0025) 2014; 73
Ross (10.1016/j.cca.2019.12.011_b0135) 2003; 40
van Beers-Tas (10.1016/j.cca.2019.12.011_b0100) 2016; 18
Shi (10.1016/j.cca.2019.12.011_b0020) 2013; 65
Wang (10.1016/j.cca.2019.12.011_b0010) 2015; 2015
Arnett (10.1016/j.cca.2019.12.011_b0130) 1988; 31
Brink (10.1016/j.cca.2019.12.011_b0030) 2015; 17
Pecani (10.1016/j.cca.2019.12.011_b0165) 2016; 18
Shi (10.1016/j.cca.2019.12.011_b0035) 2015; 17
Truchetet (10.1016/j.cca.2019.12.011_b0075) 2017; 69
Montes (10.1016/j.cca.2019.12.011_b0045) 2016; 11
Guan (10.1016/j.cca.2019.12.011_b0095) 2019; 49
Maksymowych (10.1016/j.cca.2019.12.011_b0120) 2015; 42
Reed (10.1016/j.cca.2019.12.011_b0160) 2016; 18
Gong (10.1016/j.cca.2019.12.011_b0110) 2017; 36
Tholen (10.1016/j.cca.2019.12.011_b0140) 2004; 128
Aletaha (10.1016/j.cca.2019.12.011_b0125) 2010; 69
van Venrooij (10.1016/j.cca.2019.12.011_b0005) 2011; 7
Carrier (10.1016/j.cca.2019.12.011_b0115) 2016; 18
Bergum (10.1016/j.cca.2019.12.011_b0040) 2016; 75
Ajeganova (10.1016/j.cca.2019.12.011_b0070) 2017; 76
Shovman (10.1016/j.cca.2019.12.011_b0105) 2019; 141
Verheul (10.1016/j.cca.2019.12.011_b0060) 2015; 54
Verheul (10.1016/j.cca.2019.12.011_b0145) 2018; 70
Ceccarelli (10.1016/j.cca.2019.12.011_b0170) 2018; 20
Gan (10.1016/j.cca.2019.12.011_b0065) 2015; 42
Regueiro (10.1016/j.cca.2019.12.011_b0155) 2019; 71
Massaro (10.1016/j.cca.2019.12.011_b0175) 2018; 27
References_xml – volume: 18
  start-page: 37
  year: 2016
  ident: b0115
  article-title: Serum levels of 14-3-3eta protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis
  publication-title: Arthritis Res. Ther.
– volume: 11
  year: 2016
  ident: b0045
  article-title: Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies
  publication-title: PLoS ONE
– volume: 76
  start-page: 112
  year: 2017
  end-page: 118
  ident: b0070
  article-title: The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor
  publication-title: Ann. Rheum. Dis.
– volume: 41
  start-page: 2104
  year: 2014
  end-page: 2113
  ident: b0150
  article-title: Serum 14-3-3eta is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis
  publication-title: J. Rheumatol.
– volume: 42
  start-page: 572
  year: 2015
  end-page: 579
  ident: b0065
  article-title: Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis
  publication-title: J. Rheumatol.
– volume: 20
  start-page: 126
  year: 2018
  ident: b0170
  article-title: Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus
  publication-title: Arthritis Res. Ther.
– volume: 36
  start-page: 2581
  year: 2017
  end-page: 2587
  ident: b0110
  article-title: Elevated serum 14-3-3eta protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population
  publication-title: Clin. Rheumatol.
– volume: 27
  start-page: 105
  year: 2018
  end-page: 111
  ident: b0175
  article-title: Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement
  publication-title: Lupus
– volume: 40
  start-page: 75
  year: 2003
  end-page: 78
  ident: b0135
  article-title: An improved procedure for testing for assay linearity
  publication-title: Ann. Clin. Biochem.
– volume: 49
  start-page: 57
  year: 2019
  end-page: 62
  ident: b0095
  article-title: Serum 14-3-3eta could improve the diagnostic rate of rheumatoid arthritis and correlates to disease activity
  publication-title: Ann. Clin. Lab. Sci.
– volume: 128
  start-page: 1078
  year: 2004
  ident: b0140
  article-title: Evaluation of linearity in the clinical laboratory
  publication-title: Arch. Pathol. Lab. Med.
– volume: 69
  start-page: 1580
  year: 2010
  end-page: 1588
  ident: b0125
  article-title: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
  publication-title: Ann. Rheum. Dis.
– volume: 141
  start-page: 623
  year: 2019
  end-page: 626
  ident: b0105
  article-title: Decrease in 14-3-3eta protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib
  publication-title: Pharmacol. Res.
– volume: 42
  start-page: 1587
  year: 2015
  end-page: 1594
  ident: b0120
  article-title: 14-3-3eta autoantibodies: diagnostic use in early rheumatoid arthritis
  publication-title: J. Rheumatol.
– volume: 18
  start-page: 96
  year: 2016
  ident: b0160
  article-title: Antibodies to carbamylated alpha-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies
  publication-title: Arthritis Res. Ther.
– volume: 75
  start-page: 1494
  year: 2016
  end-page: 1500
  ident: b0040
  article-title: Antibodies against carbamylated proteins are present in primary Sjogren's syndrome and are associated with disease severity
  publication-title: Ann. Rheum. Dis.
– volume: 31
  start-page: 315
  year: 1988
  end-page: 324
  ident: b0130
  article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
  publication-title: Arthritis Rheum.
– volume: 17
  start-page: 339
  year: 2015
  ident: b0035
  article-title: The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis
  publication-title: Arthritis Res. Ther.
– volume: 34
  start-page: 1650
  year: 2007
  end-page: 1657
  ident: b0090
  article-title: Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation
  publication-title: J. Rheumatol.
– volume: 71
  start-page: 331
  year: 2019
  end-page: 339
  ident: b0155
  article-title: Specific association of HLA-DRB1*03 with anti-carbamylated protein antibodies in patients with rheumatoid arthritis
  publication-title: Arthritis Rheumatol.
– volume: 108
  start-page: 17372
  year: 2011
  end-page: 17377
  ident: b0015
  article-title: Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage
  publication-title: PNAS
– volume: 68
  start-page: 2090
  year: 2016
  end-page: 2098
  ident: b0055
  article-title: Role of anti-carbamylated protein antibodies compared to anti-citrullinated protein antibodies in indigenous North Americans with rheumatoid arthritis, their first-degree relatives, and healthy controls
  publication-title: Arthritis Rheumatol.
– volume: 54
  start-page: 1930
  year: 2015
  end-page: 1932
  ident: b0060
  article-title: Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent
  publication-title: Rheumatology
– volume: 73
  start-page: 780
  year: 2014
  end-page: 783
  ident: b0025
  article-title: Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis
  publication-title: Ann. Rheum. Dis.
– volume: 69
  start-page: 2292
  year: 2017
  end-page: 2302
  ident: b0075
  article-title: Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: data from the French ESPOIR Cohort
  publication-title: Arthritis Rheumatol.
– volume: 17
  start-page: 25
  year: 2015
  ident: b0030
  article-title: Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage
  publication-title: Arthritis Res. Ther.
– volume: 70
  start-page: 2096
  year: 2018
  end-page: 2097
  ident: b0080
  article-title: Anti-carbamylated protein antibodies and higher baseline disease activity in rheumatoid arthritis-a replication study in three cohorts: comment on the article by Truchetet et al.
  publication-title: Arthritis Rheumatol.
– volume: 75
  start-page: 1575
  year: 2016
  end-page: 1576
  ident: b0050
  article-title: Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation
  publication-title: Ann. Rheum. Dis.
– volume: 18
  start-page: 276
  year: 2016
  ident: b0165
  article-title: Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases
  publication-title: Arthritis Res. Ther.
– volume: 65
  start-page: 911
  year: 2013
  end-page: 915
  ident: b0020
  article-title: Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis
  publication-title: Arthritis Rheum.
– volume: 16
  start-page: R99
  year: 2014
  ident: b0085
  article-title: 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage
  publication-title: Arthritis Res. Ther.
– volume: 2015
  year: 2015
  ident: b0010
  article-title: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis
  publication-title: J. Immunol. Res.
– volume: 70
  start-page: 1721
  year: 2018
  end-page: 1731
  ident: b0145
  article-title: Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals
  publication-title: Arthritis Rheumatol.
– volume: 7
  start-page: 391
  year: 2011
  end-page: 398
  ident: b0005
  article-title: Anti-CCP antibodies: the past, the present and the future
  publication-title: Nat. Rev. Rheumatol.
– volume: 18
  start-page: 76
  year: 2016
  ident: b0100
  article-title: A prospective cohort study of 14-3-3eta in ACPA and/or RF-positive patients with arthralgia
  publication-title: Arthritis Res. Ther.
– volume: 18
  start-page: 276
  year: 2016
  ident: 10.1016/j.cca.2019.12.011_b0165
  article-title: Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/s13075-016-1173-0
– volume: 73
  start-page: 780
  year: 2014
  ident: 10.1016/j.cca.2019.12.011_b0025
  article-title: Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/annrheumdis-2013-204154
– volume: 54
  start-page: 1930
  year: 2015
  ident: 10.1016/j.cca.2019.12.011_b0060
  article-title: Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/kev250
– volume: 141
  start-page: 623
  year: 2019
  ident: 10.1016/j.cca.2019.12.011_b0105
  article-title: Decrease in 14-3-3eta protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2018.11.009
– volume: 42
  start-page: 572
  year: 2015
  ident: 10.1016/j.cca.2019.12.011_b0065
  article-title: Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis
  publication-title: J. Rheumatol.
  doi: 10.3899/jrheum.140767
– volume: 17
  start-page: 25
  year: 2015
  ident: 10.1016/j.cca.2019.12.011_b0030
  article-title: Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/s13075-015-0536-2
– volume: 68
  start-page: 2090
  year: 2016
  ident: 10.1016/j.cca.2019.12.011_b0055
  article-title: Role of anti-carbamylated protein antibodies compared to anti-citrullinated protein antibodies in indigenous North Americans with rheumatoid arthritis, their first-degree relatives, and healthy controls
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.39664
– volume: 69
  start-page: 2292
  year: 2017
  ident: 10.1016/j.cca.2019.12.011_b0075
  article-title: Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: data from the French ESPOIR Cohort
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.40237
– volume: 71
  start-page: 331
  year: 2019
  ident: 10.1016/j.cca.2019.12.011_b0155
  article-title: Specific association of HLA-DRB1*03 with anti-carbamylated protein antibodies in patients with rheumatoid arthritis
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.40738
– volume: 40
  start-page: 75
  year: 2003
  ident: 10.1016/j.cca.2019.12.011_b0135
  article-title: An improved procedure for testing for assay linearity
  publication-title: Ann. Clin. Biochem.
  doi: 10.1258/000456303321016204
– volume: 11
  year: 2016
  ident: 10.1016/j.cca.2019.12.011_b0045
  article-title: Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0161141
– volume: 75
  start-page: 1575
  year: 2016
  ident: 10.1016/j.cca.2019.12.011_b0050
  article-title: Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/annrheumdis-2016-209248
– volume: 128
  start-page: 1078
  year: 2004
  ident: 10.1016/j.cca.2019.12.011_b0140
  article-title: Evaluation of linearity in the clinical laboratory
  publication-title: Arch. Pathol. Lab. Med.
  doi: 10.5858/2004-128-1078a-EOLITC
– volume: 7
  start-page: 391
  year: 2011
  ident: 10.1016/j.cca.2019.12.011_b0005
  article-title: Anti-CCP antibodies: the past, the present and the future
  publication-title: Nat. Rev. Rheumatol.
  doi: 10.1038/nrrheum.2011.76
– volume: 27
  start-page: 105
  year: 2018
  ident: 10.1016/j.cca.2019.12.011_b0175
  article-title: Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement
  publication-title: Lupus
  doi: 10.1177/0961203317713141
– volume: 18
  start-page: 76
  year: 2016
  ident: 10.1016/j.cca.2019.12.011_b0100
  article-title: A prospective cohort study of 14-3-3eta in ACPA and/or RF-positive patients with arthralgia
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/s13075-016-0975-4
– volume: 2015
  year: 2015
  ident: 10.1016/j.cca.2019.12.011_b0010
  article-title: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis
  publication-title: J. Immunol. Res.
  doi: 10.1155/2015/915276
– volume: 75
  start-page: 1494
  year: 2016
  ident: 10.1016/j.cca.2019.12.011_b0040
  article-title: Antibodies against carbamylated proteins are present in primary Sjogren's syndrome and are associated with disease severity
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/annrheumdis-2015-207751
– volume: 70
  start-page: 1721
  year: 2018
  ident: 10.1016/j.cca.2019.12.011_b0145
  article-title: Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.40562
– volume: 76
  start-page: 112
  year: 2017
  ident: 10.1016/j.cca.2019.12.011_b0070
  article-title: The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/annrheumdis-2015-208870
– volume: 20
  start-page: 126
  year: 2018
  ident: 10.1016/j.cca.2019.12.011_b0170
  article-title: Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/s13075-018-1622-z
– volume: 34
  start-page: 1650
  year: 2007
  ident: 10.1016/j.cca.2019.12.011_b0090
  article-title: Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation
  publication-title: J. Rheumatol.
– volume: 36
  start-page: 2581
  year: 2017
  ident: 10.1016/j.cca.2019.12.011_b0110
  article-title: Elevated serum 14-3-3eta protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population
  publication-title: Clin. Rheumatol.
  doi: 10.1007/s10067-017-3807-2
– volume: 18
  start-page: 96
  year: 2016
  ident: 10.1016/j.cca.2019.12.011_b0160
  article-title: Antibodies to carbamylated alpha-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/s13075-016-1001-6
– volume: 16
  start-page: R99
  year: 2014
  ident: 10.1016/j.cca.2019.12.011_b0085
  article-title: 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/ar4547
– volume: 31
  start-page: 315
  year: 1988
  ident: 10.1016/j.cca.2019.12.011_b0130
  article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.1780310302
– volume: 108
  start-page: 17372
  year: 2011
  ident: 10.1016/j.cca.2019.12.011_b0015
  article-title: Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage
  publication-title: PNAS
  doi: 10.1073/pnas.1114465108
– volume: 65
  start-page: 911
  year: 2013
  ident: 10.1016/j.cca.2019.12.011_b0020
  article-title: Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis
  publication-title: Arthritis Rheum.
  doi: 10.1002/art.37830
– volume: 42
  start-page: 1587
  year: 2015
  ident: 10.1016/j.cca.2019.12.011_b0120
  article-title: 14-3-3eta autoantibodies: diagnostic use in early rheumatoid arthritis
  publication-title: J. Rheumatol.
  doi: 10.3899/jrheum.141385
– volume: 41
  start-page: 2104
  year: 2014
  ident: 10.1016/j.cca.2019.12.011_b0150
  article-title: Serum 14-3-3eta is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis
  publication-title: J. Rheumatol.
  doi: 10.3899/jrheum.131446
– volume: 18
  start-page: 37
  year: 2016
  ident: 10.1016/j.cca.2019.12.011_b0115
  article-title: Serum levels of 14-3-3eta protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/s13075-016-0935-z
– volume: 69
  start-page: 1580
  year: 2010
  ident: 10.1016/j.cca.2019.12.011_b0125
  article-title: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/ard.2010.138461
– volume: 17
  start-page: 339
  year: 2015
  ident: 10.1016/j.cca.2019.12.011_b0035
  article-title: The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/s13075-015-0860-6
– volume: 70
  start-page: 2096
  year: 2018
  ident: 10.1016/j.cca.2019.12.011_b0080
  article-title: Anti-carbamylated protein antibodies and higher baseline disease activity in rheumatoid arthritis-a replication study in three cohorts: comment on the article by Truchetet et al.
  publication-title: Arthritis Rheumatol.
  doi: 10.1002/art.40678
– volume: 49
  start-page: 57
  year: 2019
  ident: 10.1016/j.cca.2019.12.011_b0095
  article-title: Serum 14-3-3eta could improve the diagnostic rate of rheumatoid arthritis and correlates to disease activity
  publication-title: Ann. Clin. Lab. Sci.
SSID ssj0004061
Score 2.3658519
Snippet •Single and multiple indicators can be combined together for identification of RA.•Positive of any two markers or only anti-CCP tend to be diagnosed as...
As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 102
SubjectTerms 14-3-3η
Anti-carbamylated proteins antibodies (anti-CarP)
Anti-cyclic citrullinated peptide antibody (anti-CCP)
Rheumatoid arthritis (RA)
Rheumatoid factor (RF)
Title Diagnostic performance of 14-3-3η and anti-carbamylated protein antibodies in Rheumatoid Arthritis in Han population of Northern China
URI https://dx.doi.org/10.1016/j.cca.2019.12.011
https://www.ncbi.nlm.nih.gov/pubmed/31862264
https://www.proquest.com/docview/2329733932
Volume 502
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hkNpeqgJ9bAvIlTghpcSv3fiIFtBCBYcKJG5WHNsiFU1WdPfQS6_9Sf0X_U2dcZJFPcChhxzi2LHlmcx8zrwA9kMwpRCFzowfm0xF_NJN7g2eUjhHhaalMhQofHE5nl2r8xt9swbTIRaG3Cp72d_J9CSt-5bDfjcP53VNMb45FT_kBEF4kWK4lJoQl3_6-eDmQQprqKZGvQfLZvLxwuWTd5dJfwQ5f0w3PYY9kw46fQUve_DIjrr1bcJaaLbg-XSo2bYFzy56U_k2_DrunOiwK5s_RAewNjKuMpnJP79Z2Xi8FnVWkdXh2487BJ6epdQNdZOeuJa8DBnefbkNS0S3be1p_tuUC4naZ2XD5qsqYPT6ZAoK9w1Ltblfw_XpydV0lvVVF7JKarnIeJRaKVeVwRhdIrqrvIiKR1-RBbFAOBYr74SLQrncFVHlUgUXEeiZoPLCyzew3rRNeAcMoZpzGgGhc_jGwpS6KpQQeSmcmBgtRpAP-22rPiU5Vca4s4Pv2VeLJLJEIsuFRRKN4GA1ZN7l43iqsxqIaP9hKov64qlhHweCW6QfWVDKJrTL7xbhp5lIiQw3grcdJ6xWgcJxTFHJ7_9v0g_wQtBRPrm37cD64n4ZdhHvLNxeYug92Dg6-zy7_AtJWP15
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hkEovFaWvLX24Uk-VUuLXEh-rbdHyWA4VSNysOLZFEE1WdPfQS6_9SfyL_qbOOMmiHuDAIYc4fskz9nzOvAA-hmBKIQqdGT82mYq4003uDd5SOEeBpqUy5Cg8OxlPz9ThuT5fg8ngC0Nmlf3Z353p6bTuS3b71dyd1zX5-OaU_JATBOEF-XBtKNy-lMbg8-9bOw-SWEM6Nao-qDaTkRfOn8y7TPolyPldwuku8JmE0P4WPOnRI_vSTfAprIVmGzYnQ9K2bXg063Xlz-DP186KDquy-a17AGsj4yqTmfx7w8rG47Oos4rUDj9-XSHy9CzFbqib9MW1ZGbI8O37RVgivG1rT-NfpGBIVD4tGzZfpQGj7pMuKFw3LCXnfg5n-99OJ9OsT7uQVVLLRcaj1Eq5qgzG6BLhXeVFVDz6ilSIBeKxWHknXBTK5a6IKpcquIhIzwSVF16-gPWmbcIrYIjVnNOICJ3DHgtT6qpQQuSlcGLPaDGCfFhvW_UxySk1xpUdjM8uLZLIEoksFxZJNIJPqybzLiDHfZXVQET7H1dZFBj3NfswENwi_UiFUjahXf60iD_NnpTIcSN42XHCahZ4Oo7JLfn1wwZ9D5vT09mxPT44OdqBx4Lu9cnW7Q2sL66X4S2Cn4V7l5j7Hwjn_wc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnostic+performance+of+14-3-3%CE%B7+and+anti-carbamylated+protein+antibodies+in+Rheumatoid+Arthritis+in+Han+population+of+Northern+China&rft.jtitle=Clinica+chimica+acta&rft.au=Zhang%2C+Yuan&rft.au=Liang%2C+Yongming&rft.au=Feng%2C+Limei&rft.au=Cui%2C+Liyan&rft.date=2020-03-01&rft.eissn=1873-3492&rft.volume=502&rft.spage=102&rft_id=info:doi/10.1016%2Fj.cca.2019.12.011&rft_id=info%3Apmid%2F31862264&rft.externalDocID=31862264
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-8981&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-8981&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-8981&client=summon